Social media has built unrealistic expectations around glutathione, and it is worth setting the record straight
CagriSema: GI adverse events affected 79.6% in the CagriSema group vs 39.9% placebo in REDEFINE 1, including nausea, vomiting, diarrhea, constipation, and abd
The benefits and drawbacks of glutathione IV include rapid peak concentration within minutes, skin improvement in 37.5% of participants versus 18.7% placebo, and FDA approval as chemotherapy adjunct, while risks encompass adverse events in 32% of users, lack of FDA approval for skin lightening, and benefits fading after 6 months of discontinuation
En cuanto a las consideraciones dietticas especficas cuando se utilizan estos frmacos, es importante tener en cuenta que pueden causar efectos secundarios gastrointestinales como nuseas, vmitos y diarrea, especialmente al inicio del tratamiento
fda.gov